The USFDA authorized the emergency use of the Pfizer-BioNTech COVID-19 Vaccine in children aged 5 to 11 years. The vaccine is administered as a two-dose series, three weeks apart, with an efficiency of 90.7%. According to a recent statement of the acting FDA commissioner, vaccinating younger children will help us get closer to returning to normalcy.
A transparent evaluation system and advisory by the committee experts have given the emergency approval of the Pfizer-BioNTech COVID-19 vaccine approved to prevent the infection in children of age 5 to 11. In addition, extensive monitoring of vaccine safety has helped in assuring the parents and guardians of the high standards the vaccine has achieved for its approval. How the study was conducted Available data ensuring vaccine safety More than 4,600 participants aged 5 to 11 (3,100 vaccines, 1,538 placebo) enrolled in this study for the…
